相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Jacson K. Shen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma Results of a Phase 2 Trial (SARC 005)
Martee L. Hensley et al.
CANCER (2013)
Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2013)
Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Gerold Bepler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M. Pollack et al.
CANCER (2012)
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma
N. Rainusso et al.
CANCER GENE THERAPY (2012)
Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy
Angela J. Ziebarth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group
Satoshi Kawaguchi et al.
CANCER SCIENCE (2012)
Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma
Nourredine Himoudi et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis
Jin-Ping Lai et al.
MODERN PATHOLOGY (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection
Manfred Lehner et al.
PLOS ONE (2012)
NY-ESO-1 expression in sarcomas A diagnostic marker and immunotherapy target
Jin-Ping Lai et al.
ONCOIMMUNOLOGY (2012)
Trends in Survival for Patients With Metastatic Soft-Tissue Sarcoma
Antoine Italiano et al.
CANCER (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Addition of Muramyl Tripeptide to Chemotherapy for Patients With Newly Diagnosed Metastatic Osteosarcoma
Alexander J. Chou et al.
CANCER (2009)
Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression
Nabil Ahmed et al.
MOLECULAR THERAPY (2009)
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor β
Shuang Wei et al.
CANCER RESEARCH (2008)
Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future
Robert G. Maki
ONCOLOGIST (2007)
Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5
Tomohide Tsukahara et al.
CANCER SCIENCE (2006)
Rhabdomyosarcoma lysis by T cells expressing a human autoantibody- based chimeric receptor targeting the fetal acetylcholine receptor
S Gattenlohner et al.
CANCER RESEARCH (2006)
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
W Schwinger et al.
ANNALS OF ONCOLOGY (2005)
Interferon-α as the only adjuvant treatment in high-grade osteosarcoma:: Long term results of the Karolinska Hospital series
CR Müller et al.
ACTA ONCOLOGICA (2005)
Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma
S Kawaguchi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma
KM Leu et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
分享论文
